Trudy Lieberman

The private market has failed to deliver affordable long-term care insurance. Washington state has another plan.

Is the government serious about attacking super-high drug prices by paying only for those with proven benefit for patients? The Aduhelm decision will be a critical tell.

Sustained coverage on surprise bills fueled public outrage and legislation. But the resulting regulations are far from perfect.

A trio of reporters offer a masterful examination of the overuse, underuse and misuse of medical care in America.

Comparing Medicare plans proves tough sledding — even for a veteran journalist tracking such plans for decades.

Why Medicare advocates worry deeply about any moves that erode the program’s universal reach among seniors.

If drug price negotiation fails, Democrats lose funding for much of their current health care plans.

While hospitals often deflect blame to other sectors of health care, there’s no question they play an outsized role in rising costs.

The media has largely taken a pass on covering the dark side of Medicare Advantage plans, so people don't understand how the plans’ cost-sharing and provider networks really work.

The media, the medical community, and academic drug experts all quickly questioned the FDA’s approval process — a rare occurrence.